MAGE-A4/survivin helper peptide vaccine (Bioimmulance)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameMAGE-A4/survivin helper peptide vaccine (Bioimmulance)

Drug Alias Namehelper/killer-hybrid epitope long peptide vaccine (Bioimmulance Co.Ltd)

ClassificationBiologics > Protein drugs > Recombinant polypeptideVaccines > Development/production technology > Inactivated vaccine > Subunit vaccineVaccines > Application > Therapeutic vaccine

Mechanisms of ActionImmunomodulators

TargetsNot applicable

Therapy Area/IndicationsNeoplasm Metastasis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesBioimmulance

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBioimmulance

Active IndicationsN/A

Inactive IndicationsNeoplasm Metastasis

Other Information

ATC CodeN/A